• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 10:57:21 AM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email
    SC 13G/A 1 tv01070-hologicinc.htm SCHEDULE 13G/A hologicinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  Hologic Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  436440101

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  436440101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    437,229

    7.  SOLE DISPOSITIVE POWER

    26,405,598

    8.  SHARED DISPOSITIVE POWER

    1,142,449

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    27,548,047

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.72%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Hologic Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    35 Crosby Drive
    Bedford, MA 01730

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    436440101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    27,548,047

      (b) Percent of Class:

    10.72%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  437,229

    (iii)  sole power to dispose of or to direct the disposition of:  26,405,598

    (iv)  shared power to dispose or to direct the disposition of:  1,142,449

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $HOLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    3/3/2025Buy → Hold
    Argus
    2/6/2025$80.00 → $75.00Outperform → Market Perform
    Leerink Partners
    2/3/2025Buy → Hold
    Needham
    12/13/2024Peer Perform
    Wolfe Research
    12/10/2024$90.00Buy
    Needham
    12/10/2024$85.00Hold
    Jefferies
    10/1/2024$95.00 → $85.00Buy → Neutral
    Citigroup
    6/27/2024$87.00Overweight
    Stephens
    More analyst ratings

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hologic Inc.

      SC 13G/A - HOLOGIC INC (0000859737) (Subject)

      11/14/24 1:28:29 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form SC 13G filed by Hologic Inc.

      SC 13G - HOLOGIC INC (0000859737) (Subject)

      2/14/24 10:04:34 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

      SC 13G/A - HOLOGIC INC (0000859737) (Subject)

      2/9/23 11:22:19 AM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hologic Announces Financial Results for Second Quarter of Fiscal 2025

      – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

      5/1/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

      MGH-led study retrospectively analyzed 5,000 radiologist-reviewed screening exams using the company's Genius AI® Detection Solution Hologic, Inc. (NASDAQ:HOLX) will have a strong presence at the Society of Breast Imaging (SBI) Annual Symposium in Colorado Springs, Colorado this week, including the presentation of pivotal new research conducted by a top-tier healthcare facility focused on the company's AI-driven mammography technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424821675/en/Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI In a retrospective study conducted at Ma

      4/24/25 8:10:00 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

      Report highlights efforts to enhance access and equity in women's health and invest in the future with science-based environmental targets, employee development and community engagement Hologic, Inc. (NASDAQ:HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect women, today released its annual sustainability report with an emphasis on expanded environmental commitments and efforts to advance access and equity in women's health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422781805/en/Hologic 2024 Sustainability Report For almost four decades

      4/22/25 8:08:00 AM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Hologic Inc.

      10-Q - HOLOGIC INC (0000859737) (Filer)

      5/2/25 8:05:04 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HOLOGIC INC (0000859737) (Filer)

      5/1/25 4:02:02 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Hologic Inc.

      SCHEDULE 13G/A - HOLOGIC INC (0000859737) (Subject)

      4/17/25 9:35:36 AM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Financials

    Live finance-specific insights

    See more

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hologic Announces Financial Results for Second Quarter of Fiscal 2025

      – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

      5/1/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

      Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 6553890. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.c

      4/3/25 4:30:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic Announces Financial Results for First Quarter of Fiscal 2025

      – Company Reports GAAP Diluted EPS of $0.87; Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Revenue of $1,021.8 Million Increases 0.9%; Constant Currency Growth of 1.0% In-Line with Guidance – – Company Lowers Full-Year Guidance for GAAP EPS, Maintains Guidance for Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 28, 2024. "Our financial results for the first quarter of 2025 were consistent with our guidance overall," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Total revenue finished in line with our guidance on a constant currency basis, an

      2/5/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • New insider Liddy Anne M. claimed ownership of 11,426 shares (SEC Form 3)

      3 - HOLOGIC INC (0000859737) (Issuer)

      5/2/25 4:52:34 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Director Mcmillan Wayde D. was granted 1,742 shares (SEC Form 4)

      4 - HOLOGIC INC (0000859737) (Issuer)

      4/9/25 4:16:43 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • New insider Mcmillan Wayde D. claimed no ownership of stock in the company (SEC Form 3)

      3 - HOLOGIC INC (0000859737) (Issuer)

      4/9/25 4:11:54 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • CellMax Life Announces Expansion of Company Board With Leading Industry Experts

      Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

      4/6/23 9:00:00 AM ET
      $EXAS
      $HOLX
      Medical Specialities
      Health Care
      Medical Electronics
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 29, 2024 - FDA Roundup: October 29, 2024

      For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

      10/29/24 3:30:19 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • February 2, 2024 - FDA Roundup: February 2, 2024

      For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

      2/2/24 3:58:21 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hologic downgraded by Argus

      Argus downgraded Hologic from Buy to Hold

      3/3/25 8:06:16 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Hologic from Outperform to Market Perform and set a new price target of $75.00 from $80.00 previously

      2/6/25 7:06:39 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic downgraded by Needham

      Needham downgraded Hologic from Buy to Hold

      2/3/25 7:08:07 AM ET
      $HOLX
      Medical Electronics
      Health Care